Toy Andrew sold $408K of CLOV

Toy Andrew (Chief Executive Officer) sold 87,798 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.65 ($0.41M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Toy Andrew
Published Aug 10, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details: 87,798 shares at $4.65 totaling $408,260.70, with holdings after the trade and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is unlikely to change the fundamental outlook given the 10b5-1 framing.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide any new operational or financial guidance.

Relevance 3/10Novelty 3/10Timing: same-day SEC Form 4 filing (2026-08-10)

Background

The article is a primary-source SEC Form 4 insider transaction for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Toy Andrew filed a Form 4 open-market sale of 87,798 shares at $4.65 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and positioning rather than fundamentals.

Evidence & confidence

The filing provides transaction size, price, and that it is under a pre-arranged 10b5-1 plan, which reduces the signal of new negative information.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure could be routine rather than a bearish signal.

Key entities

  • Clover Health Investments Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • Toy Andrew

    CEO and officer/director who sold shares via an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.